DeepMed Research

SUN PHARMACEUTICAL INDUSTRIES LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.

Phase 3

Recruiting

Conditions: Moderate to Severe Genital Psoriasis

Interventions: Drug: Tildrakizumab 100 mg
Drug: Placebo

First Posted Date: 2024-09-24

Last Posted Date: 2025-05-20

Lead Sponsor: Sun Pharmaceutical Industries Limited

Target Recruit Count: 192

Registration Number: NCT06611163

Locations: 🇺🇸
Medical Dermatology Specialists, Phoenix, Arizona, United States
🇺🇸
Smary Cures Clinical Research, Anaheim, California, United States
🇺🇸
California Dermatology & Clinical Research Institute, Encinitas, California, United States

and more 69 locations

A Study to Assess Sebaceous Gland Changes and Constituents of Sebum (Skin Oil) Induced by Clascoterone 1% Cream in Acne Patients

Phase 4

Active, not recruiting

Conditions: Acne Vulgaris

Interventions: Drug: Winlevi (Clascoterone) cream 1%

First Posted Date: 2024-05-23

Last Posted Date: 2025-02-17

Lead Sponsor: Sun Pharmaceutical Industries Limited

Target Recruit Count: 10

Registration Number: NCT06425900

Locations: 🇺🇸
Dermatology Consulting Services, PLLC, High Point, North Carolina, United States

A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients

Phase 4

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Winlevi (clascoterone) 1% cream

First Posted Date: 2024-05-16

Last Posted Date: 2025-03-04

Lead Sponsor: Sun Pharmaceutical Industries Limited

Target Recruit Count: 50

Registration Number: NCT06415292

Locations: 🇺🇸
Dermatology Consulting Services, PLLC, High Point, North Carolina, United States

A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne

Phase 4

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Winlevi (clascoterone) 1% cream

First Posted Date: 2024-05-16

Last Posted Date: 2025-05-07

Lead Sponsor: Sun Pharmaceutical Industries Limited

Target Recruit Count: 10

Registration Number: NCT06415305

Locations: 🇺🇸
Skin Sciences, PLLC, Louisville, Kentucky, United States

A Study to Evaluate the Reduction in Sebum (Skin Oil) Induced by Clascoterone Cream 1% in Acne Patients

Phase 4

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Winlevi (clascoterone) 1% cream

First Posted Date: 2024-05-16

Last Posted Date: 2025-04-15

Lead Sponsor: Sun Pharmaceutical Industries Limited

Target Recruit Count: 40

Registration Number: NCT06415279

Locations: 🇺🇸
Dermatology Consulting Services, PLLC, High Point, North Carolina, United States

A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne

Phase 4

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Winlevi (clascoterone) 1% & Adapalene 0.3% gel

First Posted Date: 2024-03-29

Last Posted Date: 2025-04-06

Lead Sponsor: Sun Pharmaceutical Industries Limited

Target Recruit Count: 20

Registration Number: NCT06336603

Locations: 🇺🇸
Skin Sciences, PLLC, Louisville, Kentucky, United States

A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Duac Gel (Benzoyl Peroxide/Clindamycin) for the Treatment of Acne

Phase 4

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Winlevi (clascoterone) 1% & Duac gel

First Posted Date: 2024-03-29

Last Posted Date: 2024-10-21

Lead Sponsor: Sun Pharmaceutical Industries Limited

Target Recruit Count: 10

Registration Number: NCT06336629

Locations: 🇺🇸
Skin Sciences, PLLC, Louisville, Kentucky, United States

A Therapeutic Equivalence Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Phase 3

Completed

Conditions: Primary Open Angle Glaucoma
Ocular Hypertension

Interventions: Drug: Brinzolamide ophthalmic suspension
Drug: Azopt®

First Posted Date: 2021-08-26

Last Posted Date: 2024-01-18

Lead Sponsor: Sun Pharmaceutical Industries Limited

Target Recruit Count: 599

Registration Number: NCT05022004

Locations: 🇮🇳
Dr. BR Ambedkar Medical College and hospital, Bangalore, Karnataka, India
🇮🇳
Rising Retina Clinic, Ahmedabad, Gujarat, India
🇮🇳
Dr Agarwal's Eye Hospital, Tirunelveli, Tamil Nadu, India

and more 31 locations

Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis

Phase 3

Recruiting

Conditions: Psoriatic Arthritis

Interventions: Drug: TILD sub-cutaneous (SC) injection

First Posted Date: 2021-08-05

Last Posted Date: 2025-03-04

Lead Sponsor: Sun Pharmaceutical Industries Limited

Target Recruit Count: 650

Registration Number: NCT04991116

Locations: 🇨🇿
Sunpharma site no 36, Brno, Czechia
🇨🇿
Sunpharma site no 67, Praha 2, Czechia
🇨🇿
Sunpharma site no 89, Praha 4, Czechia

and more 90 locations

To Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Atopic Dermatitis

Phase 2

Completed

Conditions: Dermatitis, Atopic

Interventions: Drug: Placebo
Drug: SCD-044_Dose 1
Drug: SCD-044_Dose 3
Drug: SCD-044_Dose 2

First Posted Date: 2020-12-24

Last Posted Date: 2025-05-09

Lead Sponsor: Sun Pharmaceutical Industries Limited

Target Recruit Count: 250

Registration Number: NCT04684485

Locations: 🇺🇸
Stride Clinical Research, Sugar Land, Texas, United States
🇺🇸
Springville Dermatology/ CCT Research, Springville, Utah, United States
🇺🇸
Skin DC Derm, Arlington, Virginia, United States

and more 55 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy